RATIONALE DIAGNOSTIK UND THERAPIE DER OBSTRUKTIVEN ATEMWEGSKRANKHEITEN IN DER PRAXIS = DIAGNOSTIC RATIONNEL ET TRAITEMENT DES OBSTRUCTIONS DES VOIES RESPIRATOIRES EN PRATIQUEHELLMANN K.1979; THERAPIEWOCHE; DEU; DA. 1979; VOL. 29; NO 28; PP. 4572-4578; (5 P.); BIBL. 8 REF.Article

EICHUNG DER TRIAS-ZEITSKALA = ETALONNAGE DE L'ECHELLE DES TEMPS DU TRIASHELLMANN K.1978; FORSCHUNGSBER. UNIV. HEIDELBERG; DEU; DA. 1978; VOL. 1975; PP. 495Article

EFFECT OF ICRF 159 ON IMMUNE RESPONSES = EFFET DE L'ICRF 159 SUR LES REPONSES IMMUNESHELLMANN K.1972; PROC. R. SOC. MED.; G.B.; DA. 1972; VOL. 65; NO 3; PP. 264-265; BIBL. 12REF.Serial Issue

Strategies for the integration of INTRON A (interferon Alfa-2b) into the treatment of hematological malignancies: proceedings/Symposium on INTRON A: 3rd. international conference on malignant lymphoma, Lugano, June 1987HELLMANN, K.Cancer treatment reviews. 1988, Vol 15, issn 0305-7372, 65 p., suppl. AConference Proceedings

HISTAMINE RECEPTOR ANTAGONISM AND ANTI-TUMOUR ACTIVITY = ANTAGONISME DU RECEPTEUR DE L'HISTAMINE ET ACTIVITE ANTITUMORALECOLLINS M; HELLMANN K.1982; BRITISH JOURNAL OF CANCER; ISSN 0007-0920; GBR; DA. 1982; VOL. 46; NO 5; PP. 817-820; BIBL. 18 REF.; GRAPHArticle

Proceedings Paraplatin (carboplatin): new advances in cancer therapy. Update on clinical experience. Satellite symposium: 4th European conference on clinical oncology, Madrid, Spain, 2 November 1987HELLMANN, K.Cancer treatment reviews. 1988, Vol 15, issn 0305-7372, 44 p., suppl. BConference Proceedings

SYNERGISM OF ICRF 159 AND RADIOTHERAPY IN TREATMENT OF EXPERIMENTAL TUMORSHELLMANN K; MURKIN GE.1974; CANCER; U.S.A.; DA. 1974; VOL. 34; NO 4; PP. 1033-1039; BIBL. 12REF.Article

Entwicklung der Schraubtechnik = Evolution de la technologie des assemblages filetés = Development in the screwing technologyHELLMANN, K.- H.VDI-Z. 1989, Vol 131, Num 5, pp 89-93, issn 0042-1766Article

Rohstoffsicherung in der Regionalplanung am Beispiel des Raumordnungsverbandes Rhein-Neckar, der Region Unterer Necker und der Region Rheinpfalz = Garantie de matières premières dans la planification régionale sur l'exemple de l'association d'aménagement de l'espace Rhin-Neckar, de la région du Bas Neckar et de celle de Rhénanie-PalatinatHELLMANN, K. N.1986, 130 p.Book

A COMPARISON OF RESULTS OBTAINED BETWEEN TWO METHODS OF DETECTING THE EXISTENCE OF CIRCADIAN RHYTHMICITY IN CELL DIVISION: AN AUTORADIOGRAPHICAL AND A BIOCHEMICAL APPROACHCHALLONER D; SIMNET JD; HELLMANN K et al.1981; J. CELL SCI.; ISSN 0021-9533; GBR; DA. 1981; VOL. 47; PP. 249-265; BIBL. 17 REF.Article

COMBINATION OF RADIATION AND RAZOXANE (ICRF 159) IN VIVO.HELLMANN K; GRIMSHAW MB; HUTCHINSON GE et al.1978; INTERACTION J. RAD. ONCOL. BIOL. PHYS.; U.S.A.; DA. 1978; VOL. 4; NO 1-2; PP. 109-113; BIBL. 23 REF.; (INTERACTION RADIAT. ANTITUMOR DRUGS. STANFORD CADE MEM. SYMP.; LONDON; 1976)Conference Paper

SYMPOSIUM ON VINDESINEHELLMANN K ED; CARTER SK ED.1980; CANCER TREAT. REV.; ISSN 0305-7372; GBR; DA. 1980; VOL. 7; NO 3; SUPPL.; 93 P.; BIBL. DISSEM.Conference Paper

CUMULATIVE CYTOSTATIC EFFECT OF ICRF159HALLOWES RC; WEST DG; HELLMANN K et al.1974; NATURE; G.B.; DA. 1974; VOL. 247; NO 5441; PP. 487-490; BIBL. 14REF.Article

STRAHLENTHERAPIE UND ICRF 159 (NSC 129943) IN DER BEHANDLUNG INOPERABLER WEICHTEILSARKOME = LA RADIOTHERAPIE ET L'ICRF 159 (NSC 129943) DANS LE TRAITEMENT DES SARCOMES INOPERABLES DES PARTIES MOLLESRHOMBERG W; HELLMANN K; RYALL RDH et al.1974; DTSCHE MED. WSCHR.; DTSCH.; DA. 1974; VOL. 99; NO 48; PP. 2438-2442; ABS. ANGL.; BIBL. 20 REF.Article

RAZOXANE PENETRATION INTO THE CEREBROSPINAL FLUID OF RATSGREIG N; FU XIAO CHANG; HELLMANN K et al.1982; CANCER CHEMOTHER. PHARMACOL.; ISSN 0344-5704; DEU; DA. 1982; VOL. 8; NO 2; PP. 251-252; BIBL. 6 REF.Article

THE NEW DEVELOPMENTS OF CANCER TREATMENTHELLMANN K ED; CARTER SK ED.1980; CANCER TREAT. REV.; ISSN 0305-7372; GBR; DA. 1980; VOL. 7; NO 4; 100 P.; BIBL. DISSEM.Conference Paper

International symposium on modification of drug resistance, Aachen, FRG, 23 June 1990HELLMANN, K; OSIEKA, R.Cancer treatment reviews. 1990, Vol 17, issn 0305-7372, 89 p., SUPAConference Proceedings

Paraplatin (carboplatin) current status and future prospects: proceedings/3rd European conference on clinical oncologyCARTER, S. K; HELLMANN, K.Cancer treatment reviews. 1985, Vol 12, issn 0305-7372, 152 p., suppl. AConference Proceedings

Recent advances in Intron A (Interferon alfa-2B) in oncology: proceedings/ symposium on Intron A (Interferon alfa-2B): 3rd. European conference on clinical oncology, Stockholm, June 19, 1985HELLMANN, K; TURNBULL, C. P.Cancer treatment reviews. 1985, Vol 12, issn 0305-7372, 70 p., suppl. BConference Proceedings

BIOLOGICAL PROPERTIES OF ICRF-159 AND RELATED BIS(DIOXOPIPERAZINE) COMPOUNDSHERMAN EH; WITIAK DT; HELLMANN K et al.1982; ADV. PHARMACOL. CHEMOTHER.; ISSN 0065-3144; USA; DA. 1982; VOL. 19; PP. 249-290; BIBL. 5 P.Article

COMBINATION OF RADIOTHERAPY AND RAZOXANE (ICRF 159) FOR CHONDROSARCOMARYALL RDH; BATES T; NEWTON KA et al.1979; CANCER; USA; DA. 1979; VOL. 44; NO 3; PP. 891-895; BIBL. 14 REF.Article

RB-SR- UND K-AR-ALTERSBESTIMMUNGEN AN ODENWAELDER GRANITPORPHYREN. = DETERMINATIONS DE L'AGE PAR LES METHODES RB.SR ET K.AR DE PORPHYRES GRANITIQUES DE L'ODENWALD.HELLMANN K; BREWER MS; LIPPOLT HJ et al.1972; FORTSCHR. D. MINERAL.; DEU; 1972, VOL. 50, NUM. 0001Miscellaneous

Radiotherapeutic enhancement by razoxaneHELLMANN, K; RHOMBERG, W.Cancer treatment reviews. 1991, Vol 18, Num 4, pp 225-240, issn 0305-7372Article

Management of biodiversity in protected areas with sustainability controlHELLMANN, K.WIT transactions on ecology and the environment. 2005, pp 257-266, isbn 1-8456-4013-6, 1Vol, 10 p.Conference Paper

Overview and historical development of dexrazoxaneHELLMANN, K.Seminars in oncology. 1998, Vol 25, Num 4, pp 48-54, issn 0093-7754, SUP10Article